Secondary Prevention in Patients Several Years after Myocardial Infarction: Comparison of an Outpatient and an Inpatient Rehabilitation Programme

Objective To compare the effectiveness of secondary preventive measures in patients after myocardial infarction participating in an outpatient rehabilitation programme at a university hospital with those of an inpatient programme in community hospitals. Design Cross-sectional study of patients several years after myocardial infarction. Methods Seven hundred patients who survived myocardial infarction in the period from 1 January 1989 to 31 December 1995 were chosen from archives of the university hospital (350 patients) and from archives of two community hospitals (350 patients). The patients from the university hospital attended an outpatient rehabilitation programme, while the patients from the community hospitals attended an inpatient rehabilitation programme. The data were obtained by questionnaire, clinical examination and laboratory blood analyses. Results One hundred and eighty patients attending an outpatient and 140 patients attending an inpatient rehabilitation programme responded to the invitation. Among those who were smokers at the time of myocardial infarction, 91% of patients from the outpatient programme versus 77% of patients from the inpatient programme (P < 0.05) gave up smoking and were still non-smokers; 69% versus 48% (P < 0.05) had a lipid-modified diet; 21% versus 36% (P < 0.05) were obese (BMI > 30 kg/m2). Blood pressure > 140/90 mmHg was found in 21% versus 58% (P < 0.05); total cholesterol > 5.0 mmol/l in 67% versus 87% (P < 0.05); and fasting glucose > 5.6 mmol/l in 43% versus 63% (P < 0.05) of patients from the outpatient and the inpatient programmes, respectively. Among prophylactic drug treatments higher usage of beta-blocking agents (56% versus 36%; P < 0.05) and lipolytic agents (43% versus 23%; P < 0.05) and no significant difference in usage of antiplatelet drugs (83% versus 75%) and angiotensin-converting enzyme inhibitors (30% versus 32%) was found in patients from the outpatient programme compared to patients from the inpatient programme. Only regular physical activity was performed better by patients from the inpatient programme than by patients from the outpatient programme (68% versus 50%; P < 0.05). Conclusions The outpatient rehabilitation programme of the university hospital resulted in better application of secondary prevention than the inpatient rehabilitation programme of community hospitals. J Cardiovasc Risk 8:119-126 © 2001 Lippincott Williams & Wilkins.

[1]  H A Dewar,et al.  The primary prevention of myocardial infarction. , 2009, Scandinavian journal of haematology. Supplementum.

[2]  D. Stewart,et al.  Cardiac rehabilitation II: referral and participation. , 2002, General hospital psychiatry.

[3]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[4]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[5]  S Goya Wannamethee,et al.  Changes in physical activity, mortality, and incidence of coronary heart disease in older men , 1998, The Lancet.

[6]  N. Campbell,et al.  Secondary prevention clinics for coronary heart disease: randomised trial of effect on health , 1998, BMJ.

[7]  D Kromhout,et al.  The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. , 1997, European heart journal.

[8]  M. Laakso,et al.  Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. , 1997, Atherosclerosis.

[9]  K. Pyörälä CHD prevention in clinical practice , 1996, The Lancet.

[10]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[11]  C. Blauth,et al.  Prevention and management of cardiovascular disease in patients with diabetes mellitus: an evidence base. , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[12]  T. Bowker,et al.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). , 1996, Heart.

[13]  D. Brand,et al.  Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. , 1995, Journal of the American College of Cardiology.

[14]  J. Cutler,et al.  Blood Pressure and Mortality Among Men With Prior Myocardial Infarction , 1995 .

[15]  V. Fuster,et al.  Preventing heart attack and death in patients with coronary disease. , 1995, Circulation.

[16]  R S Paffenbarger,et al.  Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. , 1995, JAMA.

[17]  V. Bittner Primary and secondary prevention of ischemic heart disease. , 1994, Current opinion in cardiology.

[18]  P. Touboul,et al.  Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease , 1994, The Lancet.

[19]  D. Rogers,et al.  Literature Reviews: Endocrinology , 1994 .

[20]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[21]  L. Valenti,et al.  Secondary prevention after acute myocardial infarction. , 1993, The American journal of cardiology.

[22]  R S Paffenbarger,et al.  The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. , 1993, The New England journal of medicine.

[23]  K. Swedberg,et al.  Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.

[24]  R. D'Agostino,et al.  Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. , 1991, BMJ.

[25]  P. Elwood,et al.  EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART) , 1989, The Lancet.

[26]  J. Paniagua,et al.  [Cholesterol and high-density lipoprotein cholesterol in acute myocardial infarct]. , 1988, Medicina clinica.

[27]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[28]  S. Taylor Secondary Prevention After Myocardial Infarction: Facts and Fallacies , 1984, Journal of cardiovascular pharmacology.

[29]  R. J. Bondar,et al.  Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. , 1974, Clinical chemistry.

[30]  P. Fu,et al.  Enzymatic determination of total serum cholesterol. , 1974, Clinical chemistry.

[31]  G Bucolo,et al.  Quantitative determination of serum triglycerides by the use of enzymes. , 1973, Clinical chemistry.

[32]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[33]  E. C. Hammond,et al.  Coronary heart disease, stroke, and aortic aneurysm. , 1969, Archives of environmental health.

[34]  C. Gohlke-Bärwolf,et al.  Cardiac rehabilitation: where are we going? , 1998, European heart journal.

[35]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .

[36]  J. Cruickshank Beta-blockers: primary and secondary prevention. , 1992, Journal of cardiovascular pharmacology.